Moving Away From Classical Chemotherapeutics

1807 Words Dec 11th, 2014 8 Pages
Moving away from Classical Chemotherapeutics:
A Review of Recent Advances in Targeted Chemotherapy

As an elegant manipulation of the cell cycle, cancer pathways have demanded significant attention by the world’s researchers. From molecular biology to inorganic chemistry, each field has conducted a variety of studies to elucidate the pathways cancer manipulates in order to develop successful treatments. To this end, chemotherapy emerged as a prominent research field in the early 1960s and is a type of cancer treatment that uses drugs to stop or slow the growth of cancer cells.1 Classical chemotherapeutics began with cisplatin and expanded to develop more potent second and third generation analogues, such as oxaliplatin and carboplatin (Figure 1).2,3 Classical chemotherapeutics are types of drugs that interfere with DNA replication or the mitotic processes of tumor cells.4 In this way, cisplatin and its analogues were developed to interfere with the cell cycle of tumor cells and considered efficient because more cancer cells are killed than healthy cells during treatment.4 As the model system for treatment, cisplatin efficiently targets cancer cells for apoptosis by creating crosslinks in DNA.1 While successful in clinical treatments, classical chemotherapeutics have severe side effects that are associated with the killing of healthy cells.5 Classical chemotherapeutics have been successful in treating several types of cancer, including testicular, ovarian, cervical, and…
Open Document